The host range of HAV is limited to man, apes (especially the chimpanzee), and several species of New World 'monkeys (2) . Viral replication is limited to the liver, and excretion into the stool appears to occur via the biliary system. The 27-nm virion. of HAV was first observed in 1973 (3) and first isolated in tissue culture in 1979 (4) . Its cultivation remains difficult,, impeding analysis of molecular structure and events in replication.
HAV has been classified as a picomavirus (5) . It has a sedimentation coefficient of approximately 160 S and a primary buoyant density of 1.34 g/ml in CsCl. Virion capsid polypeptides of Mr 32,000, 26,000, 22,000, and 10,000 have been described. The single-stranded infectious RNA genome is 6,700 to 8,100 nucleotides long and contains poly(A), presumably at the 3' terminus. By analogy with other picornaviruses the RNA should contain an open reading frame of about 6 ,500 nucleotides, which.directs synthesis of a polyprotein that is post-translationally cleaved into virion proteins. These include the four capsid proteins, a peptide linked to the 5' end of the genome (VPg), a RNA-dependent RNA polymerase, anda protease (6-9).
Previously, von der Helm et al. (10) described cloned cDNAs of up to 1,000 base pairs that hybridized to RNA extracted from.
HAV labeled in tissue culture. We report here the cloning of cDNA representing at least .99% -of the genome of HAV and partial analysis of its sequence.
MATERIALS AND-METHODS Source and Propagation of HAV. The HM-175 strain of HAV was isolated from a family outbreak in Australia (11) . HAV that had been passaged twice in marmosets (Saguinus mystax and Saguinus labiatus) (11) was inoculated into eight marmosets. A 20% (wt/vol) suspension of HAV-infected liver in phosphatebuffered saline was injected intravenously, and animals were monitored by serum enzymes and immunofluorescence of liver biopsy (12) . When maximum immunofluorescence was reached. 10-14 days after inoculation, the marmosets were killed and their livers were immediately removed, minced, frozen in liquid N2, and stored at -70'C until virus purification.
HAV was. also passaged 6 times in marmosets and 19 times in secondary African green monkey. kidney (AGMK) monolayers (11), which were used as a source of RNA for hybridization (see below). Infected cultures were harvested at 21 days when 100% of the cells exhibited maximal immunofluorescence.
Virus Purification. Minced marmoset livers (total, 170 g) were homogenized, extensively extracted with trichlorotrifluoroethane and chloroform, and treated with micrococcal nuclease (13) . Virus was monitored'by radioimmunoassay (14) and by electron microscopy during successive sucrose, CsCl, and sucrose gradients.
RNA Extraction and Characterization. Suspensions of purified HAV were incubated at 370C for 15 min with 500 ,Ag of proteinase K per ml, after which NaDodSO4 was added to a concentration of 0.5%, and incubation was continued for an additional 30 min. After extraction with phenol. and then with chloroform/isoamyl alcohol (24:1, vol/vol),. RNA was precipitated in ethanol, redissolved, and, after removal of a portion for analysis, reprecipitated. RNA was characterized by UV spectroscopy and agarose gel electrophoresis after denaturation with 1 M glyoxal/50% dimethyl sulfoxide (vol/vol) (15) . Other portions were used to analyze template quality and optimal. conditions for cDNA synthesis as described in Results and Fig. 1 . RNA for-hybridization studies was prepared from uninfected and HAV-infected (see above) ACGMK.cellsrby isolation of total cytoplasmic RNA (16) . Polyadenylylated RNA was isolated by oligo(dT)-cellulose chromatography (17) . RNA was transferred to nitrocellulose paper after electrophoretic separation through agarose gels containing glyoxal/dimethyl sulfoxide-denatured RNA (18 After phenol extraction, column chromatography, and ethanol precipitation, double-stranded cDNA (ds cDNA) was digested for 1 hr at 370C using nuclease S1 at 10 units/ml (0.1 unit per ng of ds cDNA) in 30 mM NaOAc (pH 4.5)/0.3 M NaCl/3 mM ZnCl2/5% glycerol (vol/vol), followed by addition of EDTA to 35 mM, phenol and ether extraction, and dialysis against 10 mM Tris HCl (pH 7.5) and 1 mM EDTA (8) .
Homopolymer tails of dCMP were added to ds cDNA 4sing terminal deoxynucleotidyltransferase (250. units/ml) for 20 min at room temperature in 100 ,ul that contained 0.14 M potassium cacodylate (pH 7.2)/1 mM CoCl2/0.2 mM dithioerythritol/nuclease-free bovine serum albumin (500 ,ug/ml)/200 ,uM dCTP (8) . After phenol extraction, 50% of the ds cDNA was ether-extracted and precipitated with ethanol.
The remaining tailed ds cDNA was applied to a 3-ml column of Sepharose 4B in 20 mM Tris-HCl (pH 8.0)/0.6 M NaCl/2 mM EDTA (16) . The first five 65-,l fractions containing ds cDNA were pooled and precipitated in ethanol after the addition of 2 ,ug of yeast tRNA.
Plasmid vector pBR322, cleaved at the Pst I site and tailed with dGMP, was hybridized to equimolar amounts of both tailed ds cDNA preparations and used to transform E. coli HB1O1 by standard procedures (16) .
Analysis of cDNA Clones. Clones containing putative HAV sequences were screened by cleaving recombinant plasmid preparations with Pst I and sizing by gel electrophoresis. Cloned cDNA inserts isolated from low melting point agarose (19) were labeled by nick-translation and used as probes in hybridization (i) to electrophoretically separated RNA bound to nitrocellulose paper (described above) for establishing the identity of cloned cDNA species, (ii) to DNA bound to nitrocellulose paper after lysis of bacterial colonies in situ for further screening, and (iii) to restriction, fragments of DNA resolved by electrophoresis and bound to nitrocellulose paper for confirmation of tentative restriction maps constructed on the basis of single and double enzyme digests. Extent of RNA sequence not represented in cDNA clones was determined by primer extension of HAV-infected AGMK cytoplasmic RNA (8) . Sequence determination of cloned cDNA was by the method of Maxam and Gilbert (20) . cer Institute; nuclease S1, P-L Biochemicals; terminal deoxynucleotidyltransferase, nuclease-free bovine serum albumin, nicktranslation kits, and certain restriction endonucleases, Bethesda Research Laboratories; other restriction enzymes, New England BioLabs; Sepharose 4B, Pharmacia; and oligo(dG)-tailed pBR322, New England Nuclear. "2I-Labeled anti-HAV from the HAVAB kit (Abbott) was used for detection of HAV by radioimmunoassay (14) .
RESULTS
Virus Purification and RNA Characterization. Direct electron microscopic examination of purified HAV particles revealed a homogeneous population of 27-nm virions. The yield of virion RNA from eight marmoset livers was approximately 1.0 Aug and the A2w/A2w ratio was 2.0. Samples used for UV spectroscopy were also denatured and analyzed by electrophoresis through an agarose gel (15) . HAV RNA contained a discrete band comigrating with poliovirus type 1 RNA (approximately 7,440 nucleotides; refs. 7-9).
Analytic cDNA Synthesis. RNAs from several sources of HAV and from poliovirus type 2 were compared for template quality in cDNA synthesis under conditions optimal for poliovirus RNA (Fig. 1) . HAV RNA derived from liver or AGMK culture yielded a series of transcripts ranging in size from slightly smaller than the longest poliovirus type 2 cDNA to less than 500 nucleotides (Fig. 1, lanes a, b, and b' ; lanes e and e' show poliovirus type 2 cDNA). Presumably, degradation of HAV RNA prevented more extensive synthesis of reverse transcript approaching the expected full length of 7,500 nucleotides. Other HAV cDNAs in Fig. 1 (lanes c and d) degradation, but all gave a similar banding pattern that was different from that of poliovirus cDNAs. The effect of varying several chemical constituents and physical parameters on yield and length of HAV cDNA was analyzed bsy alkaline agarose gel electrophoresis and incorporation of P]dCMP into trichloroacetic acid-precipitable product (data not shown). Incubation for 30 min, or with reverse transcriptase at 120 units/ml, or with 100 mM KC1 increased size and quantity of cDNA when compared to that shown in Fig. 1 (lane b') . Denaturation of HAV RNA was not attempted because quantity was limited and, in earlier experiments, heat or methylmercury treatment of poliovirus RNA decreased yield and size of cDNA.
Preparation of cDNA Clones. A significant portion of HAV cDNA transcribed under preparative conditions was 3,000-7,500 nucleotides long (Fig. 2, lane a) . However, a wide size range of ds cDNA molecules was produced (Fig. 2, lane b) , and most of the preparation was less than 2,000 nucleotides long after nuclease SI digestion From this group, only pHAVL 1307 (described below) was extensively characterized.
Identity of Cloned cDNA. The identity of inserted DNAs in recombinant plasmids was established by hybridization to RNA bound to nitrocellulose paper after gel electrophoresis (Fig. 3) .
A nick-translated probe prepared from the insert of pHAVLB 39 specifically hybridized to RNA from HAV-infected AGMK cells (Fig. 3, lanes c' and e) . Similar results (not shown) were obtained when the inserts of pHAVLB 93 or pHAVLB 228 were used as probes. The predominant band identified had the size expected for genomic HAV RNA and comigrated with poliovirus type 2 RNA. Diffuse hybridization to lanes containing RNA from infected cells was probably due to RNA degradation. Nicktranslated pBR322 did not hybridize to any RNA species from either HAV-infected or uninfected AGMK cells (data not shown), thereby eliminating the possibility that a small amount of pBR322 contaminating the insert probes was responsible for specific hybridization. None of the pHAVLB probes tested to date hybridized to poliovirus RNA.
Restriction Map of Cloned HAV cDNAs. The restriction map shown in Fig. 4 is based on data obtained from digests and on hybridization of labeled inserts to fractionated DNA (data not shown). Hybridization of an insert fragment from pHAVLB 228 [corresponding to the region from 2.4 to 3.0 kilobases (kb) in Fig. 4 ] to DNA from bacterial colonies was used to select pHAVL 1307 (and pHAVLB 12 and pHAVLB 153, described in the legend to Fig. 4) an open reading frame initiated by an ATG, followed by poly(A), presumed to represent the 3' end of the viral genome. The longest possible polypeptide encoded in the second and third reading frames is 29 amino acids. Preliminary sequence data (unpublished results) indicate that an open reading frame begins with an ATG approximately 750 bases from the 5' end of HAV RNA and continues for at least 378 bases. Numerous stop codons in the other reading frames preclude a significant translation product. DISCUSSION Molecular cloning of cDNA is a useful approach for the study of RNA viruses such as HAV. Analysis of virion structure and HAV replication has been limited by the persistence of cellular functions in HAV-infected tissue culture, the long time required for virus proliferation, and the small quantities of HAV obtainable. The availability of cloned HAV cDNA, made possible by using efficient conditions for ds cDNA synthesis that were well characterized for another picornaviral RNA (8), should be useful for deducing RNA and amino acid sequences and elucidating the events of replication.
In an effort to produce cDNA clones that contained only HAV sequences, HAV RNA was extracted from highly purified virions. HAV RNA probably represents a very small proportion of nucleic acid from potential sources. The virus appears, from electron microscopic (21) and biophysical data (unpublished data), to be associated with intracellular membranous vesicles in vivo and in vitro. It is possible that nonviral nucleic acid species could contaminate HAV preparations by copurifying with the virus or associated membranes. In earlier experiments the template for cDNA was RNA extracted from HAV that had been incompletely purified from marmoset liver. The cDNA clones derived from this RNA were found to contain nonviral sequences that were presumably of host origin (unpublished data). In the experiments described here, liver homogenates were hydrocarbon-extracted until an aqueous-organic interphase layer was no longer detected. Micrococcal nuclease digestion was used to eliminate unencapsidated nucleic acids. In addition, any viral probe (labeled RNA or cDNA) used to screen clones might be as contaminated with nonviral sequences as the template used for cloning. Instead of using such a probe, pHAV inserts were characterized by restriction analysis, cross-hybridization, and hybridization to HAV RNA contained in RNA from a heterologous source.
It would be difficult at present to directly determine the sequence of HAV RNA as a reference, but analysis of cloned cDNA sequences described here is consistent with a genome that has the structural organization of other picornaviruses but does not show significant homology to members of this group (7) (8) (9) 22) . Although there is only one known serotype of HAV, a restriction site variation between HAV cDNA inserts was detected. It is impossible to determine whether the alteration is due to RNA sequence heterogeneity or an error in reverse transcription. However, it would not be surprising to find sequence heterogeneity, because the HAV used in this study was not cloned. The Nde I site variation (2.5 kb from the 5' end of the genome) occurs in an area that corresponds to the sequence coding for the NH2 terminus of VP1 in poliovirus RNA (7) (8) (9) . This polypeptide is thought to be important in picornaviral surface structure and in immunity (23) (24) (25) . In other picornaviruses, strain and serotype differences are often manifested by changes in VP1 RNA sequence (9, 26, 27) .
It may be feasible to use HAV cDNA as a probe to detect viral or virus-related sequences from a variety of specimens. Experiments (data not shown) using a dot blot assay (18) Nucleotide sequence of cloned cDNA corresponding to the HAV genome 3' terminus. Sequence was determined for the insert from pHAVLB 93 (20) , starting near the A va I/Xho I site (Fig. 4) (28) or eukaryotes (29) as has been done for other picornaviruses (24, 25) . Immunogenic peptides or polypeptides would have obvious potential for vaccine development.
